<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00758342</url>
  </required_header>
  <id_info>
    <org_study_id>MS-06-01</org_study_id>
    <nct_id>NCT00758342</nct_id>
  </id_info>
  <brief_title>Azopt (Brinzolamide 1.0%) Plus Travatan (Travoprost 0.004%) in Treating Patients With Chronic Angle-Closure Glaucoma (CACG)</brief_title>
  <official_title>A Double-Masked, Parallel-Group, Efficacy and Safety Study of Brinzolamide 1.0% (AZOPT) as Adjunctive Therapy to Travoprost 0.004% (TRAVATAN) in Patients With Chronic Angle-Closure Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the IOP (Intraocular Pressure) lowering efficacy and safety of Brinzolamide 1.0%
      (Azopt), dosed twice daily as adjunctive therapy in patients treated with Travoprost 0.004%
      (Travatan) once daily. The study is double masked. The patients will receive either treatment
      for 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty of enrolling patients
  </why_stopped>
  <start_date>May 2006</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean IOP (Intraocular Pressure)</measure>
    <time_frame>Screening: Week 12; (At 9 am and 4 pm time points)</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Travoprost 0.004% + Brinzolamide 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Travoprost 0.004% + Tears Natural</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Travoprost 0.004% (once daily) + Tears Naturale (twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost 0.004% + Brinzolamide 1.0%</intervention_name>
    <description>Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)</description>
    <arm_group_label>Travoprost 0.004% + Brinzolamide 1.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost 0.004% + Tears Natural</intervention_name>
    <description>Travoprost 0.004% (once daily) + Tears Naturale (twice daily)</description>
    <arm_group_label>Travoprost 0.004% + Tears Natural</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years;

          -  CACG (Chronic Angle Closure Glaucoma) ≥ 1eye

          -  have been treated with PGA (prostaglandin analogues) once daily ≥ 2 weeks prior to the
             screening visit and IOP=19-32 mmHg (millimeters mercury) in at least one eye and ≤ 32
             mmHg in both eyes

          -  clinical stability of VA (Visual Acuity) and optic nerve throughout the study

        Exclusion Criteria:

          -  Abnormality restricts exam of the fundus or anderior chamber

          -  conjunctivitis, keratitis or uveitis

          -  unable to be discontinued from using all ocular hypotensive medication(s) except
             Travatan (Travoprost 0.004%) and/or Azopt (Brinzolamide 1.0%) for 12days-4weeks

          -  ocular surgery prior to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Alcon Call Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2008</study_first_submitted>
  <study_first_submitted_qc>September 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2008</study_first_posted>
  <results_first_submitted>September 10, 2009</results_first_submitted>
  <results_first_submitted_qc>January 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2010</results_first_posted>
  <last_update_submitted>February 23, 2010</last_update_submitted>
  <last_update_submitted_qc>February 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Benny Li, Regional Scientific Clinical Affaires Manager</name_title>
    <organization>Alcon Research</organization>
  </responsible_party>
  <keyword>IOP lowering efficacy and safety of Azopt plus Travatan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Angle-Closure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
    <mesh_term>Brinzolamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Travoprost 0.004% + Brinzolamide 1.0%</title>
          <description>Travoprost 0.004% + Brinzolamide 1.0%</description>
        </group>
        <group group_id="P2">
          <title>Travoprost 0.004% + Tears Natural</title>
          <description>Travoprost 0.004% + Tears Natural</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Travoprost 0.004% + Brinzolamide 1.0%</title>
          <description>Travoprost 0.004% + Brinzolamide 1.0%</description>
        </group>
        <group group_id="B2">
          <title>Travoprost 0.004% + Tears Natural</title>
          <description>Travoprost 0.004% + Tears Natural</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean IOP (Intraocular Pressure)</title>
        <time_frame>Screening: Week 12; (At 9 am and 4 pm time points)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Travoprost 0.004% + Brinzolamide 1.0%</title>
            <description>Travoprost 0.004% + Brinzolamide 1.0%</description>
          </group>
          <group group_id="O2">
            <title>Travoprost 0.004% + Tears Natural</title>
            <description>Travoprost 0.004% + Tears Natural</description>
          </group>
        </group_list>
        <measure>
          <title>Mean IOP (Intraocular Pressure)</title>
          <units>mm Hg (millimeters mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>9 AM measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.58" spread="4.29"/>
                    <measurement group_id="O2" value="20.59" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 PM measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.11" spread="4.50"/>
                    <measurement group_id="O2" value="18.50" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Travoprost 0.004% + Brinzolamide 1.0%</title>
          <description>Travoprost 0.004% + Brinzolamide 1.0%</description>
        </group>
        <group group_id="E2">
          <title>Travoprost 0.004% + Tears Natural</title>
          <description>Travoprost 0.004% + Tears Natural</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Confidentiality agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, Ltd</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

